Why did they choose docetaxel in the 120 patient registration trial and not the protocol of the Indian 49 patient NSCLC trial? Because docetaxel, as a single agent, has been approved by the FDA to treat 2nd line NSCLC but not 1st line NSCLC.
Market Data 
Markets
AI
